Responses of Mastomys coucha, that have been infected with Brugia malayi and treated with diethylcarbamazine or albendazole, to re-exposure to infection
Authors: M.A. Khan1; R.L. Gaur1; S. Dixit1; M. Saleemuddin2; P.K. Murthy1
Source: Annals of Tropical Medicine and Parasitology, Volume 98, Number 8, December 2004 , pp. 817-830(14)
Publisher: Maney Publishing
Abstract:
The responses of Mastomys coucha to re-exposure to infection with homologous infective larvae (L3) of Brugia malayi were investigated, after initial infections with the nematode had been treated subcutaneously for 5 days with diethylcarbamazine (DEC; 150 mg citrate/kg. day) or albendazole (ALB; 50 mg/kg. day). The parasite burdens, serum concentrations of IgG reacting with a soluble somatic extract of adult B. malayi (BmAS), and cytokine and lym phocyte-proliferative responses to filarial antigen (BmAS) or mitogen (concanavilin A or lipopolysaccharide) were studied. The results demonstrated, for the first time, that re-infection with L3 was only successful in the DEC-treated animals, not the ALB-treated ones. When the ALB-treated animals were re-exposed, interferon-
production decreased, lymphocyte-proliferative responses either remained the same (with concanavilin A) or decreased (with BmAS), and concentrations of specific IgG decreased. When the DEC-treated animals were re-exposed, microfilaraemias re-appeared and, although production of interferon-
decreased, there were no detectable lymphocyte proliferative responses, and concentrations of specific IgG remained unchanged. Taken together, the results indicate that, at least in the M. coucha model of human filariasis, ALB but not DEC treatment may help to prevent the development of re-infections.
Document Type: Research article
DOI: 10.1179/136485904X12386
Affiliations: 1: Division of Parasitology, Central Drug Institute, Lucknow, 226001, India 2: Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh, 202 002, India

Click here for Page Help